Notice: This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. CDIO, BMRA, TRIB, VRAX, AWH, TNFA, MYMD, NAVB, IDXX, and LNTHShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include Cardio Diagnostics (CDIO), Biomerica (BMRA), Trinity Biotech (TRIB), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), and Lantheus (LNTH). These companies are all part of the "medical" sector. Akers Biosciences vs. Cardio Diagnostics Biomerica Trinity Biotech Virax Biolabs Group Aspira Women's Health TNF Pharmaceuticals MyMD Pharmaceuticals Navidea Biopharmaceuticals IDEXX Laboratories Lantheus Akers Biosciences (NASDAQ:AKER) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends. Does the media favor AKER or CDIO? In the previous week, Cardio Diagnostics had 3 more articles in the media than Akers Biosciences. MarketBeat recorded 3 mentions for Cardio Diagnostics and 0 mentions for Akers Biosciences. Cardio Diagnostics' average media sentiment score of 0.96 beat Akers Biosciences' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Overall Sentiment Akers Biosciences Neutral Cardio Diagnostics Positive Does the MarketBeat Community favor AKER or CDIO? Akers Biosciences received 303 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 72.92% of users gave Akers Biosciences an outperform vote. CompanyUnderperformOutperformAkers BiosciencesOutperform Votes30772.92% Underperform Votes11427.08% Cardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% Do analysts prefer AKER or CDIO? Cardio Diagnostics has a consensus price target of $2.00, suggesting a potential upside of 426.59%. Given Cardio Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Akers Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akers Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of AKER or CDIO? 5.5% of Akers Biosciences shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 0.3% of Akers Biosciences shares are owned by insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, AKER or CDIO? Akers Biosciences has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.61, suggesting that its share price is 261% more volatile than the S&P 500. Is AKER or CDIO more profitable? Akers Biosciences has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Akers Biosciences' return on equity of -87.42% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Akers BiosciencesN/A -87.42% -73.31% Cardio Diagnostics -22,732.03%-258.85%-191.20% Which has better earnings and valuation, AKER or CDIO? Akers Biosciences has higher revenue and earnings than Cardio Diagnostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkers Biosciences$1.58M3.79-$3.89MN/AN/ACardio Diagnostics$34.89K567.63-$8.38MN/AN/A SummaryCardio Diagnostics beats Akers Biosciences on 10 of the 16 factors compared between the two stocks. Remove Ads Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.00M$2.44B$5.63B$7.84BDividend YieldN/A0.72%5.33%4.01%P/E RatioN/A6.1123.6018.74Price / Sales3.7946.00388.2390.77Price / CashN/A15.7538.1734.64Price / Book0.072.986.894.23Net Income-$3.89M-$65.73M$3.20B$247.47M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.36+0.3%N/A-84.9%$6.00M$1.58M0.004CDIOCardio Diagnostics2.8617 of 5 stars$0.43-4.0%$2.00+362.9%-73.3%$22.53M$35,688.000.001Short Interest ↓BMRABiomerica0.9649 of 5 stars$0.71+3.6%N/A-30.1%$13.02M$5.58M-2.0960Short Interest ↓News CoveragePositive NewsTRIBTrinity Biotech1.4765 of 5 stars$0.66-6.1%N/A-67.5%$12.00M$59.13M-0.29480Upcoming EarningsAnalyst ForecastVRAXVirax Biolabs Group1.6622 of 5 stars$1.28+4.9%N/A+61.8%$4.14M$84,872.000.005Short Interest ↓Positive NewsGap UpAWHAspira Women's Health2.0456 of 5 stars$0.09+7.5%$4.40+4,556.1%-96.6%$1.67M$8.96M-0.08110Earnings ReportShort Interest ↓News CoverageGap DownHigh Trading VolumeTNFATNF PharmaceuticalsN/A$0.36-4.2%N/AN/A$995,000.00N/A0.006MYMDMyMD PharmaceuticalsN/A$0.38+3.4%N/A-84.9%$893,000.00N/A0.006Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00+50.0%N/A-98.9%$30,000.00$8,126.000.0010Gap UpIDXXIDEXX Laboratories4.2515 of 5 stars$423.60+0.6%$533.75+26.0%-23.0%$34.34B$3.90B39.7010,800Analyst DowngradeNews CoveragePositive NewsLNTHLantheus4.2788 of 5 stars$99.44+1.8%$129.43+30.2%+54.5%$6.81B$1.53B16.55700 Remove Ads Related Companies and Tools Related Companies Cardio Diagnostics Alternatives Biomerica Alternatives Trinity Biotech Alternatives Virax Biolabs Group Alternatives Aspira Women's Health Alternatives TNF Pharmaceuticals Alternatives MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives IDEXX Laboratories Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
